Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Analysts at Berenberg Bank


Share on StockTwits

Berenberg Bank assumed coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research note issued to investors on Wednesday morning, PriceTargets.com reports. The firm issued a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Piper Sandler raised their price objective on shares of Nurix Therapeutics from $40.00 to $60.00 and gave the stock an overweight rating in a research note on Wednesday, February 17th. Needham & Company LLC reissued a buy rating and set a $44.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, February 17th. JPMorgan Chase & Co. raised their price objective on shares of Nurix Therapeutics from $34.00 to $56.00 and gave the stock an overweight rating in a research note on Friday, January 29th. Finally, Zacks Investment Research raised shares of Nurix Therapeutics from a sell rating to a hold rating in a research note on Tuesday, December 15th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $46.80.

NASDAQ:NRIX opened at $29.03 on Wednesday. Nurix Therapeutics has a 52 week low of $15.21 and a 52 week high of $52.38. The stock’s fifty day moving average is $34.19 and its two-hundred day moving average is $35.07.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Monday, April 12th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.18). As a group, analysts anticipate that Nurix Therapeutics will post -2.05 EPS for the current fiscal year.

In related news, insider Gwenn Hansen sold 800 shares of the stock in a transaction on Monday, March 1st. The stock was sold at an average price of $35.95, for a total value of $28,760.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Christine Ring sold 1,200 shares of the stock in a transaction on Monday, April 12th. The shares were sold at an average price of $27.20, for a total value of $32,640.00. Following the completion of the sale, the general counsel now owns 2,005 shares of the company’s stock, valued at $54,536. The disclosure for this sale can be found here. Insiders sold a total of 18,430 shares of company stock worth $623,987 over the last ninety days.

Several institutional investors have recently made changes to their positions in NRIX. BlackRock Inc. raised its holdings in shares of Nurix Therapeutics by 74.7% during the fourth quarter. BlackRock Inc. now owns 1,169,974 shares of the company’s stock valued at $38,470,000 after buying an additional 500,176 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Nurix Therapeutics by 5.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 591,636 shares of the company’s stock valued at $19,453,000 after buying an additional 28,890 shares during the period. Northern Trust Corp boosted its stake in shares of Nurix Therapeutics by 3.4% during the 4th quarter. Northern Trust Corp now owns 137,812 shares of the company’s stock valued at $4,531,000 after buying an additional 4,474 shares during the period. State Street Corp acquired a new stake in shares of Nurix Therapeutics during the 3rd quarter valued at $4,597,000. Finally, Nuveen Asset Management LLC boosted its stake in shares of Nurix Therapeutics by 47.9% during the 4th quarter. Nuveen Asset Management LLC now owns 98,841 shares of the company’s stock valued at $3,250,000 after buying an additional 31,991 shares during the period. Institutional investors own 81.99% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Recommended Story: Buy Rating

Analyst Recommendations for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.